A Turning Point in MASH
A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.
By
HH Kim
January 8, 2026
1
MASH affects an estimated 115 million people globally and is the most severe form of nonalcoholic fatty liver disease.
2
Novo Nordisk's acquisition of Akero Therapeutics highlights the strategic importance of MASH in cardiometabolic medicine.
3
Recent clinical data suggest targeting metabolic regulators may improve treatment outcomes for MASH.
4
The global market for MASH treatments could exceed $20 billion by 2030, driven by major pharmaceutical players.
5
The future of MASH treatment will focus on systemic metabolic health rather than just fibrosis regression.
